Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07599813 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites revised (85)v4
  2. Study sites revised (85)v3
  3. Start date changed from estimate of May 15, 2026 to May 28, 2026
    • Study description expanded, about 17 words
    • Study sites revised (85)
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.
Trial Details
NCT Number NCT07599813
Lead Sponsor Apollo Therapeutics Ltd
Conditions
(from sponsor)		 Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
Related terms Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases
Enrollment 280 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov